Tirzepatide Research Guide — Dual GIP/GLP-1 Agonist for Metabolic Studies

## Introduction

Tirzepatide represents a significant advancement in incretin-based therapeutic research. As the first approved dual agonist of both GIP and GLP-1 receptors, it has reshaped metabolic disease investigation. Marketed clinically as Mounjaro for T2D and Zepbound for weight management, tirzepatide is supplied here as a research-grade compound for laboratory investigation purposes only.

With over 299 PubMed-verified studies and a substantial evidence base from the SURPASS and SURMOUNT clinical trial programs, tirzepatide is one of the most extensively characterized peptides in its class.

## Mechanism of Action

Tirzepatide is a 39-amino acid synthetic peptide that functions as a dual agonist with approximately equal binding affinity to both GIP and GLP-1 receptors.

**GIP Receptor Activation:** Stimulates glucose-dependent insulin secretion, promotes adipose tissue blood flow, and enhances lipid buffering.

**GLP-1 Receptor Activation:** Delays gastric emptying, slows nutrient absorption, suppresses appetite through central action on hypothalamic nuclei.

**Synergistic Effects:** The dual mechanism produces effects exceeding the sum of individual receptor contributions.

## Research Applications

**SURPASS Program (T2D):** Superior HbA1c reduction versus all comparators including semaglutide, insulin glargine, and insulin degludec.

**SURMOUNT-1 (Obesity):** Up to 22.5% mean body weight reduction at 72 weeks (15mg dose), with 96% achieving ≥5% weight loss.

## Dosage & Administration

Standard titration schedule (4-week intervals): 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg. SubQ once weekly.

## Reconstitution Guide

Reconstitute with 1mL bacteriostatic water directed against the inner vial wall. Swirl gently—do not shake. Allow 5-10 minutes for complete dissolution. Store at 2-8°C; use within 30 days.

## Safety & Side Effects

Common: nausea, diarrhea, vomiting, constipation, dyspepsia, injection site reactions, decreased appetite. Contraindicated in medullary thyroid carcinoma history, MEN-2, and severe GI disease.

## References

- PeptideWiki

- PubMed: 299+ studies

- SURPASS and SURMOUNT publications